Citations

Clear

3042 citation(s) found for "Kumar, S".

Abstract 16570: Benchmarking Risk-Adjusted Outcomes in Congenital Heart Surgery
Subramanyan, Ram Kumar, Thibault, Dylan, O’Brien, Sean M. , Shahian, David M. , Bacha, Emile , Badhwar, Vinay , Caldarone, C.A., Fernández, Félix G. , Pasquali, Sara K. , Rainey, Tabitha, Romano, Jennifer C., Shashidharan, Subhadra, Tweddell, James S., Mayer, John E. , Gaynor, J. William , Dearani, Joseph A. , Jacobs, Jeffrey P. , Overman, David M.

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.16570 Get It

Background: Robust models exist to predict risk-adjusted mortality following congenital heart surgery. It is known that underlying diagnosis modifies predicted risk of operations, and institution-level outcomes vary based on their unique case mix. We therefore evaluated risk-adjusted outcomes for a subset of diagnosis-procedure (D-P) combinations within the Society of Thoracic Surgeons' (STS) congenital heart surgery database (CHSD). Methods: A clinician panel identified the most frequently encountered D-P combinations in CHSD between 07/2017 and 06/2021. Candidate modeling techniques were compared in a random 80% development cohort. Model performance was assessed using internal and cross-validation calibration, discrimination plots and optimism adjusted C-statistics. The final selected model was evaluated in the 20% validation sample. Results: The chosen subset of D-P combinations represented 45,384 of 87,589 (52%) unique episodes of surgical care in CHSD during this time-period. The development cohort (36,350 episodes) had 1.8% mortality (667 deaths). All candidate models had excellent discrimination with C-statistics ranging from 0.862 to 0.876. The model with the best combination of discrimination, calibration, and clinical face validity was a modified version of the current STS mortality risk model. This version included all current risk model variables with the addition of indicator variables for D-P combinations. In the 20% validation sample (9,034 episodes), this model was well calibrated (Figure) and had excellent discrimination (C = 0.879). Conclusion: We describe a cohort of D-P combinations widely encountered in the STS CHSD. Further, we refined the existing STS CHSD risk model for application to these D-P dyads to derive empirical risk-adjusted benchmark outcomes. This approach will benefit quality improvement efforts at an institutional level and may have implications for publicly reporting congenital heart surgery outcomes.
Abstract 16025: Impact of COVID-19 on Major Adverse Cardiovascular and Cerebrovascular Events in Metabolically Healthy Obese (MHO) Individuals: A National Inpatient Sample Analysis, 2020
Vuddandam, Dinesh Kumar , Muvva, Durga Mounika, James, Alpha , Mallapu, Prathistitha, Nallapothula, Shantha, Katukuri, Nishanth , Chiluka, Swetha , Adelli, Raja Anvesh Reddy, Kotharu, Devi Meghana, Polavarapu, Vaibhavi, Mandadi, Leela Krishna prasad, Kanagala, Sai Gautham , Desai, Rupak

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.16025 Get It

Background: The obesity paradox is a phenomenon observed in certain chronic diseases, particularly cardiovascular diseases, where individuals with obesity have better outcomes compared to those of normal weight. We aimed to study how COVID-19 affects MACCE results in metabolically healthy obese (MHO) individuals who have a BMI >30. Methods: Using the National Inpatient Sample (2020) and appropriate ICD-10-CM codes, we identified adult hospitalizations with COVID-19 and grouped them into two cohorts with and without obesity (MHO+ and MHO-, omitting hypertension, diabetes, and hyperlipidemia). MACCE (all-cause inpatient mortality, cardiac arrest, including ventricular fibrillation, and stroke) in COVID-19-related hospitalizations was the primary outcome. Results: 84,145 (21.9%) of 397,040 COVID-19 hospitalizations were MHO+. The MHO+ group was younger (median 43 vs 52 years), female (56.9% vs. 49.4%), black (19.4% vs 15.1%), Hispanic (35.2% vs 30.5%), and Native American (1.5% vs 1.2%) (p<0.001). Tobacco use disorder, past PCI, prior VTE, depression, chronic pulmonary disease, hypothyroidism, and other thyroid problems were more common in MHO+ patients (p<0.05). MHO+ patients were discharged routinely (76% vs. 66.7%) but stayed longer (5 days vs 4 days). After correcting for baseline variables, the MHO+ cohort had a lower rate of MACCE than the MHO- cohort (8% vs. 11.3%, OR 0.81, 95CI 0.74-0.89, p<0.001), and lower all-cause mortality (6.6 % vs 9.4%) compared to the MHO- cohort. On subgroup analysis, females had lower odds (aOR 0.79) than males (aOR 0.82), older individuals ≥65 years old had lower odds (aOR 0.71) vs 45-64 (aOR 0.79), and race- wise comparison, whites had lower odds of MACCE events (aOR 0.76). Conclusions: MHO+ patients had lower odds of MACCE events. The MHO group was younger, suggesting higher cardiorespiratory fitness, which could explain the obesity paradox and reduced odds of MACCE outcomes.
Abstract 14177: Alarming Burden and Disparities of MACCE in Postmenopausal Women of a Contemporary Nationwide Cohort, 2020
Sampath, Shrikanth , Srivastava, Archit , Suchday, Pooja , Bhanushali, Aditi K, MEHTA, KAMYA, Behera, Alkananda , Eppalapally, Akhil kumar, Bollampalli, Ram Prasanjith Reddy, Desai, Rupak

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.14177 Get It

Background: Cardiovascular disease is the leading cause of death worldwide, with a notable impact on postmenopausal women. However, contemporary large-scale population-based data for the burden and disparities of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) in this population remains limited. Methods: The National Inpatient Sample (2020, ICD10 codes, age>55 years) was queried to identify postmenopausal women's hospitalizations. Socio-demographics, racial subgroups, comorbidities, and MACCE rates were retrieved with a more granular comparative analysis in postmenopausal women. A p<0.05 was considered statistically significant. Results: Of the total 8435195 postmenopausal women hospitalizations (median age 75 years), 1021375 (12.1%) were identified with MACCE. MACCE cohort, in comparison to non-MACCE cohort, had significantly higher prevalence of hypertension (77.1% vs 71.3), diabetes (39.8% vs 34.0%), hyperlipidemia (53.7% vs 48.4%), PVD (9.8% vs 7.1%), prior MI (8.3 vs 5.7%), prior TIA/stroke (10.5 vs 9%) and CKD (29.4 vs 23.4%). Significant clinical predictors for all-cause mortality were found to be race Asian/PI vs white ( 1.31 [1.09-1.18]), median household income national quartile (1.16 [1.13-1.20]), hypertension (1.18[1.16-1.20]) diabetes (1.20 [1.19-1.22]), hyperlipidemia (1.12[1.11-1.14]), prior MI (1.37[1.34-1.40]) and prior TIA stroke (1.0 5 [1.03-1.07] (all p<0.05). Conclusion: Among hospitalizations, Asian/Pacific Islanders, patients from the lowermost income quartile with co-existent hypertension, diabetes, hyperlipidemia, CKD, and cardiovascular comorbidities independently revealed the highest MACCE rates. Special emphasis needs to be laid on socio-demographics, comorbidities, and racial differences for CVD disease prevention, and risk factor modification in postmenopausal women.
Abstract 18539: The Impact of Prophylactic Heparin on Pocket Hematoma Formation After Cardiac Implantable Electronic Device Implantation a Real-World Experience
Patel, Harsh , Peters, Garrett , Mazimba, Sula , Deshmukh, Abhishek , Mehta, Nishaki, Agarwal, Siddharth , Agarwal, Siddharth , Kumar, Ashish , Agarwal, Siddharth

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18539 Get It

Introduction: Intravenous heparin is strongly associated with pocket hematoma (PH) formation in patients undergoing cardiac implantable electronic device (CIED) implantation. However, there is no data on subcutaneous prophylactic heparin in this population Hypothesis: We hypothesized that the subcutaneous heparin may increase the odds of PH in patients undergoing CIED implantation using data from a large, nationally representative sample of the US population. Methods: The Premier Healthcare Database was analyzed from 2016-2019 to identify patients >18 years old undergoing CIED implantation. Patients with PH were then identified by using ICD-10 CM codes. A multivariable logistic regression model was used to adjust for confounders Results: A total of 267,650 patients underwent CIED implantation between January 1, 2016, and December 31, 2019, of which 4,496 (1.68%) \developed PH. Single chamber pacemaker in 7.22%, dual-chamber pacemaker was implanted in 58.3% of patients, and CRT-P in 4.59%, ICD in 18.58%, CRT-D in 11.31%. Of the total cohort, 559 Patients received subcutaneous heparin within 3 days of the CIED implant procedure. Of these 559 patients, 91 (16%) patients were on subcutaneous heparin (pre-procedural: 19; post-procedural: 57) and developed PH. Subcutaneous heparin is associated with increased odds (OR :13.8,p<0.01) of PH formation. Conclusions: This study suggests that subcutaneous heparin is a strong risk factor for the development of PH. This may independently drive up the rates of PH in the inpatient population. Further studies on the timing of subcutaneous heparin need to be conducted.
Surgically Resected Cardiac Angiosarcoma: Survival Analysis from the National Cancer Database
Rahouma, Mohamed , Baudo, Massimo , Khairallah, Sherif , Lau, Christopher , Gaudino, Mario , Ahmed, Magdy M. El‐Sayed , Kumar, Akshay , Lorusso, Roberto , Mick, Stephanie L., El-Sayed Ahmed, Magdy M , Gaudino, Mario , Lorusso, Roberto , Kumar, Akshay , Rahouma, Mohammed

Mayo Clinic

Journal of Clinical Medicine | December 18, 2023 | Volume: 12 | Issue: 24 | Pages: 7764

10.3390/jcm12247764 | PMID 38137833 Get It

Angiosarcoma is a rare type of soft-tissue sarcoma arising from endothelial cells. It is considered ‘high-grade’ by definition, reflecting its aggressive behavior. We sought to investigate the role of surgery in cardiac angiosarcoma, identify late mortality predictors, and identify interactions with other modalities in its treatment using a national dataset. The 2004–2017 National Cancer Database was reviewed for patients with primary cardiac angiosarcoma. Late mortality predictors were evaluated with Kaplan–Meier curves and Cox regression analysis. Surgery in primary cardiac angiosarcoma was performed in 130 patients (median age 50.5 years; female sex 36.9%). The median follow up was 72.02 months, with a median overall survival (OS) of 14.32 months. In patients treated with surgery in combination with other modalities compared with those treated with surgery alone, median OSs were 17.28 and 2.88 months, respectively (log-rank = 0.018). Older patients (age > 57 years) experienced lower OS compared to those with an age < 57 (log-rank = 0.012). This may be partially explained by the difference in treatment strategies among age groups: those with increasing age, less surgery (p = 0.037), and less chemotherapy (p < 0.001) were chosen. With multivariable Cox regression analysis, age and race other than white or black were identified to be significant independent predictors of late mortality. Cardiac angiosarcoma has poor overall survival, and our findings should further encourage the use of surgery in combination with other therapeutic modalities in treating such an aggressive disease whenever possible.
Age-associated changes in lineage composition of the enteric nervous system regulate gut health and disease
Kulkarni, Subhash , Saha, Monalee , Slosberg, Jared , Singh, Alpana , Nagaraj, Sushma , Becker, Laren , Zhang, Chengxiu , Bukowski, Alicia, Wang, Zhuolun, Liu, Guosheng , Leser, Jenna , Bakhshi, Shriya, Vincent, Elizabeth , Pasricha, Pankaj J. , Singh, Alpana , Nagaraj, Sushma , Kulkarni, Subhash , Kumar, Mithra R. , Anderson, Matthew J , Lewandoski, Mark , Goff, Loyal A.

Mayo Clinic

eLife | December 18, 2023 | Volume: 12 | Issue: No issue available | Pages: No page available

10.7554/elife.88051.2 Get It

The enteric nervous system (ENS), a collection of neural cells contained in the wall of the gut, is of fundamental importance to gastrointestinal and systemic health. According to the prevailing paradigm, the ENS arises from progenitor cells migrating from the neural crest and remains largely unchanged thereafter. Here, we show that the lineage composition of maturing ENS changes with time, with a decline in the canonical lineage of neural-crest derived neurons and their replacement by a newly identified lineage of mesoderm-derived neurons. Single cell transcriptomics and immunochemical approaches establish a distinct expression profile of mesoderm-derived neurons. The dynamic balance between the proportions of neurons from these two different lineages in the post-natal gut is dependent on the availability of their respective trophic signals, GDNF-RET and HGF-MET. With increasing age, the mesoderm-derived neurons become the dominant form of neurons in the ENS, a change associated with significant functional effects on intestinal motility which can be reversed by GDNF supplementation. Transcriptomic analyses of human gut tissues show reduced GDNF-RET signaling in patients with intestinal dysmotility which is associated with reduction in neural crest-derived neuronal markers and concomitant increase in transcriptional patterns specific to mesoderm-derived neurons. Normal intestinal function in the adult gastrointestinal tract therefore appears to require an optimal balance between these two distinct lineages within the ENS.
Plasmapheresis in the ICU
Hussein, Guleid , Liu, Bolun , Yadav, Sumeet K. , Warsame, Mohamed , Jamil, Ramsha , Surani, Salim , Khan, Syed Anjum , Surani, Salim , Khan, Syed Anjum , Yadav, Sumeet Kumar , Liu, Bolun

Mayo Clinic

Medicina | December 12, 2023 | Volume: 59 | Issue: 12 | Pages: 2152

10.3390/medicina59122152 | PMID 38138254 Get It

Therapeutic plasma exchange (TPE) is a treatment paradigm used to remove harmful molecules from the body. In short, it is a technique that employs a process that functions partially outside the body and involves the replacement of the patient’s plasma. It has been used in the ICU for a number of different disease states, for some as a first-line treatment modality and for others as a type of salvage therapy. This paper provides a brief review of the principles, current applications, and potential future directions of TPE in critical care settings.
Causal Structure Learning from Imperfect Longitudinal Data in Healthcare
Yang, Haoyu , Tourani, Roshan , Steinbach, Michael , Kumar, Vipin , Simon, György , Li, Jia , Caraballo, Pedro J.

Mayo Clinic

2023 IEEE 11th International Conference on Healthcare Informatics (ICHI) | December 11, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.1109/ichi57859.2023.00013 Get It

Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Kumar, Shaji , Adekola, Kehinde , Anderson, Larry D. , Costello, Caitlin, D’Angelo, Christopher R. , Elsedawy, Noura, Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo, Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Robinson, Timothy, Sborov, Douglas W. , Valent, Jason , Varshavsky‐Yanovsky, Asya, Snedeker, Jenna, Holmberg, Leona , Anderson, Larry D , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Castillo, Jorge J. , Costello, Caitlin , Devarakonda, Srinivas , Garfall, Alfred L. , Htut, Myo , Kang, Yubin , Lee, Hans C. , Martin, Thomas G. , Rosenberg, Aaron , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 11, 2023 | Volume: 21 | Issue: 12 | Pages: 1281-1301

10.6004/jnccn.2023.0061 | PMID 38081133 Get It

The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several new options. These include new combinations with second generation proteasome inhibitors (PI); second generation immunomodulators, monoclonal antibodies, CAR T cells, bispecific antibodies, selinexor, venetoclax, and many others. Most patients with MM undergo several cycles of remissions and relapse, and therefore need multiple lines of combination therapies. Selecting treatment options for relapsed/refractory MM requires consideration of resistance status to specific classes, and patient-specific factors such as age and other comorbidities should be considered. The NCCN Guidelines for MM provide a framework on which to base decisions regarding workup, treatment, and follow-up of newly diagnosed and previously treated MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to relapsed/refractory disease.
Congenital Myasthenic Syndromes (CMS) Due to Impaired Principal Coupling Pathway in the ɛ Subunit of Muscle Acetylcholine Receptor (AChR) (P2.031)
Shen, Xin‐Ming , Brengman, Joan M., Shen, Shelley , Durmuş, Hacer , Deymeer, Feza , Sine, Steven M. , Engel, Andrew, Preethish‐Kumar, Veeramani , Yüceyar, Nur , Vengalil, Seena , Nalini, Atchayaram

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p2.031 Get It